Brian Lee, CEOPBS Biotech steps into this challenge with an innovative approach to cell therapy manufacturing. The company brings personalized, life-changing treatments to patients without compromising quality.
It serves the global allogeneic cell therapy market by assisting therapeutic drug developers to make treatments more accessible to a broader patient population. However, the mission goes beyond supporting these immediate developers.
“While our primary target is drug manufacturers, the end goal is always about improving patient outcomes. We manufacture single-use bioreactors in larger volumes and faster timelines, enabling researchers to develop cell therapy products that combat chronic conditions like cancer, diabetes and heart failure,” says Brian Lee, CEO.
PBS Biotech offers customized, scalable solutions and services by leveraging its innovative Vertical-Wheel technology and deep industry expertise. From expansion to differentiation phases of cell therapy development, the company plays a vital role in advancing this transformative field.
A New Paradigm to Suspension Culture
Unlike traditional bioreactors designed for monoclonal antibodies or recombinant proteins, PBS Biotech’s solutions are built specifically for human cell therapies. Its VerticalWheel bioreactors stand out in the market by providing gentle and uniform mixing, creating an optimal environment for cells to grow and differentiate in suspension.
Human cells, in contrast to their predecessors (CHO or E. coli cells) are highly sensitive and require personalized care. Whether it is pluripotent stem cells (PSC), mesenchymal stem cells (MSC), or immune cells like CAR-T and NK cells, each type has unique requirements. For instance, some grow in aggregates, while others thrive on microcarriers.
All of these factors need to be carefully monitored and optimized to ensure the highest quality and yield in human cell manufacturing. PBS Biotech’s systems adapt seamlessly to the varying needs of every cell type. The company also provides auxiliary equipment for perfusion and oxygenation to meet specific process requirements.
“Our technology is more than equipment; it’s a complete solution tailored to the industry’s needs, ensuring reliability and consistency at every stage,” says Lee
This approach is particularly crucial in large-scale operations, where additional oxygenation is required. The surface KLA (oxygen transfer rate) that works well at small scales becomes insufficient as the scale increases. PBS Biotech’s equipment is designed to ensure adequate oxygen levels during suspension culture, all while preventing damage to the cells from air bubbles.
Bridging the Gap from Lab to Market
The bubble-free or low-shear environments help in protecting cell viability and functionality for the efficacy of the therapy. This enables PBS Biotech to partner with clients at any stage of their journey.
For new developers, the company helps clients transition from traditional 2D cultures to advanced 3D suspension systems, scaling their processes from as small as 0.1 liters to 80 liters and beyond. It develops scalable processes for virtual companies without labs and transfers them to contract manufacturers, ensuring clinical trials proceed smoothly. Beyond providing assistance in commercialization, PBS Biotech’s field service engineers install and repair its equipment for established teams, offering hands-on training and application support.
By offering these tailored services, PBS Biotech meets clients where they are, enabling them to overcome technical and logistical hurdles with confidence and speed. The aim is to address a broad spectrum of patients' needs by delivering purpose-built technology and processes specifically designed for scalability.
PBS Biotech is also planning to increase bioreactor capacity while maintaining consistent hydrodynamic conditions, ensuring that processes can be repeated at larger scales just as they are at smaller scales. This focus on adaptability and continuous improvement positions PBS Biotech as a leader in the field.
Envisioning Tomorrow’s Cell Therapy
While the cell therapy industry is still in its early stages, PBS Biotech has a clear vision for its future. The company works closely with clients to learn from their challenges and develop innovative solutions.
The PBS-MINIPRO product line expansion launching in the second half of 2025 exemplifies this commitment. Designed for early-stage development, the new system allows clients to test multiple small-scale vessels simultaneously, accelerating the search for optimal conditions while reducing costs. Created in response to client feedback, it maintains the power and flexibility of the individual PBS-MINI while significantly accelerating the search for optimal conditions and reducing both development time and cost.
While our primary target is drug manufacturers, the end goal is always about improving patient outcomes
PBS Biotech is also planning to increase bioreactor capacity while maintaining consistent hydrodynamic conditions, ensuring that processes can be repeated at larger scales just as they are at smaller scales. This focus on adaptability and continuous improvement positions PBS Biotech as a leader in the field.
The company anticipates continuous innovation and new ideas to emerge and hopes the industry becomes more open to new systems, approaches and processes beyond what is available today. In the pursuit of advancing the field, PBS Biotech is expanding its knowledge base by closely collaborating with clients to understand their challenges and bottlenecks and to develop solutions as per their needs. Its customer-centric approach will eventually turn large-scale suspension culture for human cell therapy into a norm.
While the journey may take time— similar to how monoclonal antibodies took 30 to 40 years to become the industry standard—there is no doubt that this sector is on an unstoppable path toward significant growth and success.
Today, PBS Biotech has emerged as a leading provider of single-use bioreactor systems and process development services for the cell therapy industry. Whether a company is at the early stages of developing a therapeutic product or ready to advance into clinical trials and beyond, PBS Biotech is the ideal partner to help accelerate the commercialization of the product.
By offering the Vertical-Wheel platform and continuously enhancing it with supporting equipment and process expertise, PBS Biotech is positioned at the forefront of the industry’s evolution, untapping new possibilities for the future.
Scaling Cell Therapy from Research to Reliable Manufacturing
Cell therapy development has moved beyond proof-of-concept science into the demands of repeatable manufacturing and clinical delivery. For executives responsible for advancing these programs, the challenge no longer sits solely in demonstrating biological efficacy but in ensuring that therapies can be produced consistently, economically and at scale without introducing new risks at each stage of growth. Many programs falter not because the underlying biology fails, but because the transition from laboratory processes to production environments introduces variability, cost escalation and regulatory friction that were not addressed early enough.
A central tension defines decision-making in this space: early-stage flexibility often conflicts with downstream manufacturability. Processes designed for discovery rarely translate cleanly into compliant, large-scale production systems, forcing costly redesigns and delays. The ability to maintain continuity from early research through clinical and commercial manufacturing becomes a defining advantage. Organizations that anchor development decisions to the end-state requirements tend to avoid re-engineering cycles and preserve both timelines and capital efficiency.
"The right technology and development support help transform promising cell therapies into scalable, commercially viable treatments."
Technology architecture plays a decisive role in this continuity. Conventional bioreactor systems were originally engineered for scenarios where cells produce a therapeutic output rather than being the therapeutic product themselves. This distinction has profound implications. Sensitive, heterogeneous cell populations require controlled environments that preserve viability while enabling uniform growth across scales. Systems that introduce shear stress or inconsistent mixing conditions can compromise both quality and reproducibility, particularly as volumes increase. A platform that maintains predictable hydrodynamic conditions across different scales reduces the risk of variability and supports smoother progression from bench to manufacturing.
Process design and execution must evolve in parallel with technology. Early development decisions often carry hidden consequences that surface only in late-stage production or regulatory review. Building processes that are inherently scalable, supported by structured quality systems and aligned with regulatory expectations helps prevent these downstream liabilities. Consistency is not achieved through isolated optimization efforts but through disciplined integration of equipment, process knowledge and quality oversight from the outset. This approach ensures that reproducibility is embedded rather than retrofitted, while also improving audit readiness and documentation integrity across programs.
"Strong manufacturing processes help turn promising cell therapies into reliable treatments that can reach more patients efficiently and consistently."
Economic viability remains another defining pressure. As allogeneic therapies move toward commercialization, predictable cost structures become as important as scientific validation. Manufacturing processes must deliver repeatability without excessive resource consumption, while maintaining compliance with increasingly stringent regulatory frameworks. The ability to align process design with cost control and operational readiness determines whether promising therapies can reach patients at scale.
PBS Biotech stands out as a partner that addresses these interconnected challenges through an integrated platform and development model. It designs its vertical wheel bioreactor technology specifically for cell-based products, enabling gentle, uniform mixing that protects cell integrity while supporting scalability. By allowing users to operate on a single platform from early research through GMP production, it reduces the need for process re-engineering and preserves continuity across development stages. Its combined offering of equipment and process development services extends beyond tool delivery, providing direct support in media optimization, scale translation and process design to ensure early decisions remain viable in later stages. This integrated approach positions it as a long-term partner capable of guiding therapies from concept to clinical and commercial realization.
...Read more
SINGLE-USE Bioreactors Info
Q1
What distinguishes PBS Biotech among Top Single-Use Bioreactor Companies?
PBS Biotech has earned recognition among Top Single-Use Bioreactor Companies through its proprietary Vertical-Wheel® technology designed specifically for cell therapy manufacturing. Unlike conventional stirred-tank systems originally developed for monoclonal antibody production, the company’s bioreactors are engineered to support highly sensitive human cell cultures including induced pluripotent stem cells, mesenchymal stem cells, CAR-T cells and NK cells. Its systems create low-shear, homogenous suspension environments that improve cell viability, scalability and process consistency across different manufacturing stages. PBS Biotech also differentiates itself through its ability to support seamless scale-up from early research to commercial-scale production using the same hydrodynamic principles throughout the workflow.
Q2
How does PBS Biotech approach cell therapy manufacturing and scale-up?
Scalable process development forms the foundation of the company’s manufacturing strategy. Unlike many Single-Use Bioreactor Companies that require significant process adjustments during scale-up, PBS Biotech maintains consistent mixing conditions across its full Vertical-Wheel platform ranging from 0.1L systems to 80L commercial manufacturing bioreactors. Its technology enables researchers and therapeutic developers to transition from laboratory optimization into clinical and commercial production with reduced process variability. The company also provides process development support, oxygenation systems and perfusion capabilities tailored to the specialized demands of suspension culture for regenerative medicine and allogeneic cell therapy manufacturing.
Q3
Why is PBS Biotech relevant to the future of cell therapy manufacturing?
Cell therapy development continues to expand rapidly, increasing demand for scalable manufacturing platforms capable of supporting consistent therapeutic cell production. PBS Biotech addresses this challenge through Single-Use Bioreactor Companies solutions designed specifically for sensitive human cell cultures rather than traditional biologics manufacturing. Its Vertical-Wheel systems help developers improve oxygen transfer, reduce shear stress and maintain cell functionality during expansion and differentiation stages. The company’s technology also aligns with broader healthcare industry efforts to make allogeneic therapies more accessible by improving manufacturing efficiency and reducing production complexity.
Q4
What role does innovation play in PBS Biotech’s technology platform?
Continuous engineering refinement remains central to PBS Biotech’s scientific identity. The company combines proprietary Vertical-Wheel mixing technology, single-use vessel engineering and process control software to optimize therapeutic cell manufacturing environments. Its systems support closed-system operation, automated process control and configurable oxygenation strategies designed to improve scalability and reproducibility. Single-Use Bioreactor Companies often differentiate themselves through adaptability and process efficiency, and PBS Biotech reinforces that distinction through innovations such as the PBS-MiniPRO platform, which allows simultaneous small-scale process testing for accelerated development timelines and lower operational costs.
Q5
How does PBS Biotech support therapeutic developers and manufacturing teams?
Collaborative technical support plays an important role in the company’s operating model. PBS Biotech works closely with therapeutic developers during process optimization, technology transfer and manufacturing scale-up activities to help accelerate commercialization pathways. Its Bioprocess Research and Development team provides contract process development services alongside field support involving installation, troubleshooting and application training. Among Single-Use Bioreactor Companies, PBS Biotech stands out for combining equipment manufacturing with hands-on process expertise designed to help clients overcome technical bottlenecks in regenerative medicine production environments.
Q6
Why has PBS Biotech gained recognition in the bioprocessing industry?
Industry recognition for PBS Biotech reflects its contribution to advancing scalable cell therapy manufacturing technologies. Life Sciences Review recognized the company as SINGLE-USE Bioreactors Company of the Year for its ability to support large-scale suspension culture while maintaining cell quality and manufacturing consistency. Its systems have also gained visibility through peer-reviewed studies and global adoption across research and therapeutic development programs. This combination of Vertical-Wheel innovation, scalable manufacturing expertise and customer-focused process support continues to strengthen PBS Biotech’s standing among Single-Use Bioreactor Companies.
